	US 11,666,646 B2
	Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
Toshiro Shirakawa, Hyogo (JP); and Yoshiko Hashii, Osaka (JP)
Assigned to NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo (JP); and OSAKA UNIVERSITY, Osaka (JP)
Appl. No. 16/472,210
Filed by NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo (JP); and OSAKA UNIVERSITY, Osaka (JP)
PCT Filed Dec. 8, 2017, PCT No. PCT/JP2017/044123 § 371(c)(1), (2) Date Jun. 21, 2019, PCT Pub. No. WO2018/123507, PCT Pub. Date Jul. 5, 2018.
Claims priority of application No. JP2016-250560 (JP), filed on Dec. 26, 2016.
Prior Publication US 2019/0351038 A1, Nov. 21, 2019
Int. Cl. A61K 35/745 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 39/001153 (2018.08) [A61K 35/745 (2013.01); A61K 39/001102 (2018.08); A61P 35/00 (2018.01); A61K 2039/523 (2013.01); A61K 2039/542 (2013.01)]

20 Claims

1. An anti-tumor agent comprising an active ingredient, wherein the active ingredient is a tumor vaccine, in combination with an immunosuppression inhibitor, the tumor vaccine comprising a transformed Bifidobacterium containing:

DNA encoding a WT1 protein; and

DNA encoding a GNB/LNB substrate-binding membrane protein derived from a Bifidobacterium, wherein

the WT1 protein is expressed and displayed on a cell surface of the transformed Bifidobacterium as a fusion protein of the WT1 protein and the GNB/LNB substrate-binding membrane protein (GL-BP-WT1 fusion protein).